PFIZER INC (PFE) Cash and securities
- Total cash · latest quarter (USD): Value $8.26B; Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-28..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-28..
Cash and securities
Overview →Financial period ending 2026-06-28; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | $8.26B | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-28. $976.00M + $7.28B ≈ $8.26B |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-28. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 976.00M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 7.28B USD | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Cash and current securities | 8.26B USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Quarter-end shares | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-28 | $8.26B | (m) | $976.00M | $7.28B | (m) |
| 2026-03-29 | $9.89B | (m) | $1.70B | $8.19B | (m) |
| 2025-12-31 | $10.32B | (m) | $1.14B | $9.18B | (m) |
| 2025-09-28 | $11.47B | (m) | $1.34B | $10.12B | (m) |
| 2025-06-29 | $11.16B | (m) | $1.64B | $9.53B | (m) |
| 2025-03-30 | $15.38B | (m) | $1.43B | $13.95B | (m) |
| 2024-12-31 | $11.92B | (m) | $1.04B | $10.88B | (m) |
| 2024-09-29 | $7.94B | (m) | $1.09B | $6.85B | (m) |
| 2024-06-30 | $5.45B | (m) | $1.05B | $4.40B | (m) |
| 2024-03-31 | $8.94B | (m) | $719.00M | $8.22B | (m) |
| 2023-12-31 | $7.25B | (m) | $2.85B | $4.40B | (m) |
| 2023-10-01 | $29.39B | (m) | $3.15B | $26.25B | (m) |
| 2023-07-02 | $26.72B | (m) | $2.63B | $24.09B | (m) |
| 2023-04-02 | $18.28B | (m) | $2.17B | $16.12B | (m) |
| 2022-12-31 | $19.16B | (m) | $416.00M | $18.74B | (m) |
| 2022-10-02 | $21.47B | (m) | $1.30B | $20.18B | (m) |
| 2022-07-03 | $27.40B | (m) | $1.78B | $25.62B | (m) |
| 2022-04-03 | $19.81B | (m) | $2.47B | $17.34B | (m) |
| 2021-12-31 | $23.96B | (m) | $1.94B | $22.01B | (m) |
| 2021-10-03 | $24.85B | (m) | $1.97B | $22.89B | (m) |
| 2021-07-04 | $16.40B | (m) | $2.37B | $14.03B | (m) |
| 2021-04-04 | $10.06B | (m) | $1.77B | $8.29B | (m) |
| 2020-12-31 | $11.49B | (m) | $1.78B | $9.71B | (m) |
| 2020-09-27 | $9.45B | (m) | $1.59B | $7.86B | (m) |
| 2020-06-28 | $9.47B | (m) | $1.80B | $7.67B | (m) |
| 2020-03-29 | $4.96B | (m) | $2.15B | $2.81B | (m) |
| 2019-12-31 | $7.99B | (m) | $1.30B | $6.69B | (m) |
| 2019-09-29 | $7.05B | (m) | $2.79B | $4.27B | (m) |
| 2019-06-30 | $6.81B | (m) | $1.78B | $5.03B | (m) |
| 2019-03-31 | $9.12B | (m) | $1.94B | $7.18B | (m) |
| 2018-12-31 | $16.23B | (m) | $1.14B | $15.09B | (m) |
| 2018-09-30 | $14.81B | (m) | $3.56B | $11.26B | (m) |
| 2018-07-01 | $10.92B | (m) | $2.70B | $8.22B | (m) |
| 2018-04-01 | $9.31B | (m) | $2.30B | $7.01B | (m) |
| 2017-12-31 | $18.84B | (m) | $1.34B | $17.49B | (m) |
| 2017-10-01 | (m) | (m) | $2.78B | (m) | (m) |
| 2017-07-02 | (m) | (m) | $2.58B | (m) | (m) |
| 2017-04-02 | (m) | (m) | $4.06B | (m) | (m) |
| 2016-12-31 | (m) | (m) | $2.60B | (m) | (m) |
| 2016-10-02 | (m) | (m) | $2.09B | (m) | (m) |
| 2016-07-03 | (m) | (m) | $3.41B | (m) | (m) |
| 2016-04-03 | (m) | (m) | $2.56B | (m) | (m) |
| 2015-12-31 | (m) | (m) | $3.64B | (m) | (m) |
| 2015-09-27 | (m) | (m) | $3.10B | (m) | (m) |
| 2015-06-28 | (m) | (m) | $3.67B | (m) | (m) |
| 2015-03-29 | (m) | (m) | $3.56B | (m) | (m) |
| 2014-12-31 | (m) | (m) | $3.34B | (m) | (m) |
| 2014-09-28 | (m) | (m) | $2.44B | (m) | (m) |
| 2014-06-29 | (m) | (m) | $3.41B | (m) | (m) |
| 2014-03-30 | (m) | (m) | $2.86B | (m) | (m) |
| 2013-12-31 | (m) | (m) | $2.18B | (m) | (m) |
| 2013-09-29 | (m) | (m) | $2.05B | (m) | (m) |
| 2013-06-30 | (m) | (m) | $2.44B | (m) | (m) |
| 2013-03-31 | (m) | (m) | $2.13B | (m) | (m) |
| 2012-12-31 | (m) | (m) | $10.39B | (m) | (m) |
| 2012-09-30 | (m) | (m) | $4.51B | (m) | (m) |
| 2012-07-01 | (m) | (m) | $3.03B | (m) | (m) |
| 2012-04-01 | (m) | (m) | $2.93B | (m) | (m) |
| 2011-12-31 | (m) | (m) | $3.54B | (m) | (m) |
| 2011-10-02 | (m) | (m) | $3.71B | (m) | (m) |
| 2011-07-03 | (m) | (m) | $3.10B | (m) | (m) |
| 2011-04-03 | (m) | (m) | $730.00M | (m) | (m) |
| 2010-12-31 | (m) | (m) | $1.74B | (m) | (m) |
| 2010-10-03 | (m) | (m) | $2.18B | (m) | (m) |
| 2010-07-04 | (m) | (m) | $1.88B | (m) | (m) |
| 2010-04-04 | (m) | (m) | $1.76B | (m) | (m) |
| 2010-01-04 | (m) | (m) | $1.98B | (m) | (m) |
| 2009-12-31 | (m) | (m) | $1.98B | (m) | (m) |
| 2009-09-27 | (m) | (m) | $4.23B | (m) | (m) |
| 2009-06-28 | (m) | (m) | $2.24B | (m) | (m) |
| 2009-03-29 | (m) | (m) | $1.25B | (m) | (m) |
| 2008-12-31 | (m) | (m) | $2.12B | (m) | (m) |
| 2008-09-28 | (m) | (m) | $1.26B | (m) | (m) |
| 2008-06-29 | (m) | (m) | $820.00M | (m) | (m) |
| 2007-12-31 | (m) | (m) | $3.41B | (m) | (m) |
| 2006-12-31 | (m) | (m) | $1.83B | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |